Back to resultsIndividual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
Primary Purpose
Non-healing Wound, Thromboangiitis Obliterans
Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
Selexipag
Sponsored by
About this trial
This is an expanded access trial for Non-healing Wound
Eligibility Criteria
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04914247
Brief Title
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
Official Title
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
Study Type
Expanded Access
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Actelion
4. Oversight
5. Study Description
Brief Summary
The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-healing Wound, Thromboangiitis Obliterans
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Selexipag
10. Eligibility
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Contact
Phone
1-800-JANSSEN (1-800-526-7736)
Email
Janssenmedinfo@its.jnj.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Actelion Clinical Trial
Organizational Affiliation
Actelion
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
We'll reach out to this number within 24 hrs